At StressMarq Biosciences, we are committed to advancing neurodegenerative disease research through innovation, quality, and scientific rigor. As a trusted provider of neuroscience research tools, we support scientists with well-validated reagents designed to enable reproducible results and drive meaningful discovery. Our expanding portfolio, including protein aggregates, antibodies, and assay kits, reflects the evolving needs of the global research community.

This summer, we are excited to showcase a number of recently launched products designed to support cutting-edge research in Alzheimer’s disease, Parkinson’s disease, ALS, and related neurodegenerative disorders, alongside an exciting conference schedule that takes us to Barcelona, Spain and London, United Kingdom.

---

New Products 🌟

 

 

Alpha Synuclein Oligomer ELISA Kit

(Catalog# SKT-143)

---

Alpha synuclein oligomers represent a soluble, neurotoxic form of the presynaptic protein and are increasingly recognized as early drivers of pathology in neurodegenerative disease. These oligomeric species disrupt synaptic vesicle trafficking and neurotransmission, impairing presynaptic function well before the formation of mature fibrillar aggregates.

 

 

Tau-410 (2N3R) Wild-Type PFFs & Monomers

(Catalog# SPR-535 / SPR-534)

---

Tau 2N3R, one of six isoforms produced by MAPT alternative splicing, contributes to microtubule stabilization & axonal transport. In disease states, it undergoes abnormal phosphorylation and cleavage, which promote toxic oligomer formation and NFT development in disorders such as Alzheimer’s disease and frontotemporal lobar degeneration.

 

 

Tau 4R Antibody

(Catalog# SPC-815)

---

Elevated expression of 4R tau has been shown to drive neurodegeneration by promoting tau hyperphosphorylation, endolysosomal dysfunction, and apoptosis, demonstrating a direct causal link between increased 4R tau burden and neuronal vulnerability.

 

 

 

Amyloid Beta Aggregate Antibody

(Catalog# SPC-816)

---

Emerging evidence suggests that amyloid beta may also have context-dependent protective roles, including metal chelation, with neurotoxicity occurring when these compensatory mechanisms are overwhelmed, reinforcing Aβ aggregation as a central mechanistic target in neurodegenerative disease research.

 

---

Driving Scientific Innovation via Strategic Partnerships and Industry Collaboration

 

Recap: World Parkinson Congress 2026

Our team was pleased to attend WPC 2026 in Phoenix, AZ, from May 24-27, where we had the opportunity to connect with a diverse range of stakeholders across the Parkinson’s disease community. Throughout the conference, it was our pleasure to engage in meaningful discussions with researchers, clinicians, caregivers, and individuals with lived experience of Parkinson’s disease, each offering valuable perspectives on the challenges and priorities shaping the field today.

These conversations were both insightful and inspiring, underscoring the importance of collaboration between the scientific and patient communities in driving progress. Hearing firsthand experiences and research needs further strengthened our understanding of how critical well-validated tools and continued innovation are to advancing Parkinson’s disease research.

The event also provided an important platform to exchange ideas, build new relationships, and deepen existing partnerships across the neurodegeneration research landscape. We return from WPC 2026 encouraged by the shared commitment across the community and further reinforced in our mission to support research that accelerates discovery and ultimately improves outcomes for those affected by Parkinson’s disease.

We look forward to continuing these conversations and to participating in the next iteration of this important meeting in Quebec City, Canada in 2029.

Webinar: Biomarker Translation in Neurodegenerative Disease 

Upcoming Conferences

Scientific conferences remain a vital source of insight, inspiration, and direction. Through regular participation in leading international neuroscience and neurodegeneration meetings, our team remains connected to the forefront of discovery, gaining firsthand exposure to new research directions, advancing technologies, and shifting experimental approaches.

In Summer 2026, StressMarq will be attending two major international conferences: the Federation of European Neuroscience Societies (FENS 2026) meeting from July 6-10, and the Alzheimer’s Association International Conference (AAIC 2026) from July 12-15. These premier events bring together thousands of researchers from around the world to share advances spanning fundamental neuroscience, disease mechanisms, biomarker discovery, and therapeutic development.

• For those attending AAIC 2026 in London, we are also pleased to support the Canadian Networking Event by the CIHR Institute of Aging to be held on July 14 at 5:30 PM at Canada House. This gathering provides a valuable opportunity for Canadian researchers, trainees, and international collaborators to connect and exchange ideas, and StressMarq is proud to sponsor this initiative. Registration for conference attendees is free and available on a first-come, first-served basis via the provided link.

If you are unable to connect with us during our summer conference schedule, we will also be attending additional events in the fall, including meetings in New York City and Washington, DC. Please visit our Conferences & Meetings page to see where StressMarq will be next.

Looking Ahead

Progress in neurodegeneration research is built on collaboration. From industry partnerships to scientific conferences, the exchange of knowledge and ideas continues to be the catalyst for meaningful innovation.

As we expand our product offerings in 2026 and beyond, we look forward to strengthening these relationships, establishing new collaborations, and engaging with the global research community in advancing discovery together.